{"success":true,"data":{"pressRelease":{"id":"162028","rtpr_id":"nGNX7LMvY0-20261006","ticker":"OTLK","exchange":"NASDAQ","all_tickers":["OTLK"],"title":"Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion","author":"Globe Newswire","published_at":"2026-10-06T13:20:00.095Z","article_body":"Segment features Kevin Lundquist discussing his decision to join Outlook\nTherapeutics and the Company’s path forward following the FDA approval of\nLYTENAVA™\n\nAccess the segment here\n(https://www.globenewswire.com/Tracker?data=KPyvRMlou1T3hAaQt_65gBh1rw_Uwb2SlCKdyJZUlHSIFv_QCJmDMJoTDVsyn62aX6Zsl8m4deRJQWU3Axx7ms7SGpBQeDuvHhq9qgQEaMM=)\n\nISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=AipKltkhBnTWm5aJB47Gj1IR9w0rNoBEZVwehnE-aHvW5NsHzIHM3ufhCzKOP9o0S4FKDUZnIj-G2wuc-beRCA_PpeEA1ZUX0hoWTknULpyS8zbaZ5iQyTD4SX9clM5M)\n(Nasdaq: OTLK), a biopharmaceutical company focused on the development and\ncommercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the\ntreatment of retinal diseases, today announced that it participated in a\nVirtual Investor \"What This Means\" segment\n(https://www.globenewswire.com/Tracker?data=IpTaQlG9S2MeiDXnUMz4BkITBpe3gLZUs__jjAOmKbNWyPE2y75tTXckLd9ojX7nZLVdCG49Tnio6uGCga3hKMs7J2JBMciol19UpbKiW1yZolvfr4q7t7vW0vHgC5J1ikeKIcpt5soGEFhHuPEZdQ==)\nfeaturing Kevin Lundquist, the Company’s recently appointed Chief Financial\nOfficer\n\nIn the discussion, Mr. Lundquist shares his perspective on joining Outlook\nTherapeutics at such a pivotal time for the Company following the U.S. Food\nand Drug Administration approval of LYTENAVA, the only FDA-approved ophthalmic\nformulation of bevacizumab for the treatment of wet age-related macular\ndegeneration (wet AMD). He also discusses the opportunity ahead as Outlook\nTherapeutics advances toward the commercial launch of LYTENAVA in the United\nStates.\n\n“Joining Outlook Therapeutics at this point in the Company’s evolution was\na compelling opportunity,” said Kevin Lundquist, Chief Financial Officer of\nOutlook Therapeutics. “With FDA approval of LYTENAVA, we have entered an\nimportant new chapter as we transition into a commercial-stage company. I look\nforward to helping execute on our strategy, supporting the successful launch\nof LYTENAVA, and working to build long-term value for shareholders.”\n\nThe Virtual Investor “What This Means” segment is available to watch here\n(https://www.globenewswire.com/Tracker?data=KPyvRMlou1T3hAaQt_65gEi-AlR_EWh4DyJ0tQQIcnwVnt04K_zo_ooQTBEqjmnin_GBIXeJFprmUvch3vU35MNOJdCcXhgl_xSja3Tfnso=).\n\nAbout LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)\n\nLYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the\nUnited States for the treatment of wet AMD. In the United States, LYTENAVA\n(bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA.\nLYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing\nAuthorization granted by the European Commission in the EU and Marketing\nAuthorization granted by the Medicines and Healthcare products Regulatory\nAgency (MHRA) in the UK for the treatment of adults with wet AMD. In certain\nEuropean Union Member States, LYTENAVA must receive pricing and reimbursement\napproval before it can be sold.\n\nBevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant\nhumanized IgG1 monoclonal antibody specific to human vascular endothelial\ngrowth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of\nVEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.\nLYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with\nreceptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses\nendothelial cell proliferation, neovascularization, and vascular permeability.\nInhibition of such activity targets a pathophysiologic process that\ncontributes to vision loss.\n\nImportant Safety Information and Indication\n\nLYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF)\ninhibitor indicated for the treatment of patients with neovascular (wet)\nage-related macular degeneration (nAMD).\n\nContraindications\n\nLYTENAVA is contraindicated in patients with ocular or periocular infections,\nin patients with active intraocular inflammation, and in patients with a known\nhypersensitivity to bevacizumab products or any of the ingredients in\nLYTENAVA. Hypersensitivity reactions may manifest as severe intraocular\ninflammation.\n\nWarnings and Precautions\n\nIntravitreal injections have been associated with endophthalmitis and retinal\ndetachments. Proper aseptic injection technique must always be used when\nadministering LYTENAVA. In addition, patients should be monitored following\nthe injection to permit early treatment should an infection occur.\n\nIncreases in intraocular pressure have been noted post-injection (up to 60\nminutes) while being treated with LYTENAVA. Monitor intraocular pressure prior\nto and following intravitreal injection with LYTENAVA and manage\nappropriately.\n\nAlthough there was a low rate of arterial thromboembolic events (ATEs)\nobserved in the LYTENAVA clinical trials, there is a potential risk of ATEs\nfollowing intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal\nstroke, nonfatal myocardial infarction, or vascular death (including deaths of\nunknown cause).\n\nAdverse Reactions\n\nThe most common adverse reactions (≥1%) reported in patients receiving\nLYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous\nfloaters (2%). These are not all the possible side effects of LYTENAVA.\n\nYou are encouraged to report side effects of prescription drugs to the FDA.\n\nVisit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side\neffects to Outlook Therapeutics at 1-833-999-OTLK (6855).\n\nPlease see the full U.S. Prescribing Information for LYTENAVA here.\n\nAbout Outlook Therapeutics, Inc.\n\nOutlook Therapeutics is a biopharmaceutical company focused on the development\nand commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma\n(E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive\nU.S. FDA approval and European Commission and MHRA Marketing Authorization for\nthe treatment of wet AMD. Outlook Therapeutics commenced commercial launch of\nLYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment\nfor wet AMD.\n\nForward-Looking Statements\n\nThis press release contains statements that may or are considered\n“forward-looking statements”. All statements other than statements of\nhistorical facts are “forward-looking statements,” including those\nrelating to future events. In some cases, you can identify forward-looking\nstatements by terminology such as “anticipate,” “believe,” “can,”\n“could,” “continue,” “expect,” “may,” “on track,”\n“plan,” “potential,” “target,” “will,” or “would”, the\nnegative of terms like these or other comparable terminology, and other words\nor terms of similar meaning. These include, among others, express or implied\ndiscussions regarding the Company’s planned launch of LYTENAVA in the United\nStates and other jurisdictions and the timing thereof; expectations concerning\npotential revenue generation from sales of LYTENAVA; expectations surrounding\nmarket adoption of LYTENAVA; expectations regarding the potential impact of\nLYTENAVA in the retina community; Outlook Therapeutics’ development or\nfuture revenue plans for LYTENAVA generally; and other statements that are not\nhistorical fact. Although Outlook Therapeutics believes that it has a\nreasonable basis for the forward-looking statements contained herein, they are\nbased on current expectations about future events affecting Outlook\nTherapeutics and are subject to risks, uncertainties, and factors relating to\nits operations and business environment, all of which are difficult to predict\nand many of which are beyond its control. These risk factors include those\nrisks associated with developing and commercializing pharmaceutical product\ncandidates, risks in obtaining necessary regulatory approvals, the content and\ntiming of decisions by regulatory bodies, as well as those risks detailed in\nOutlook Therapeutics’ filings with the Securities and Exchange Commission\n(the SEC), including the Current Report on Form 8-K filed with the SEC on\nAugust 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, and future reports Outlook Therapeutics files with the SEC,\nwhich include uncertainty of market conditions and future impacts related to\nmacroeconomic factors, including as a result of the ongoing overseas\nconflicts, tariffs, and trade tensions, fluctuations in interest rates and\ninflation, and potential future bank failures on the global business\nenvironment. These risks may cause actual results to differ materially from\nthose expressed or implied by forward-looking statements in this press\nrelease. All forward-looking statements included in this press release are\nexpressly qualified in their entirety by the foregoing cautionary statements.\nYou are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. Outlook Therapeutics does\nnot undertake any obligation to update, amend, or clarify these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as may be required under applicable securities\nlaw.\n\nInvestor Inquiries:\nJenene Thomas\nChief Executive Officer\nJTC Team, LLC\nT: 908.824.0775\nOTLK@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX7LMvY0-20261006","title":"Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion","author":"Globe Newswire","ticker":"OTLK","created":"2026-10-06T13:20:00.095Z","tickers":["OTLK"],"exchange":"NASDAQ","article_body":"Segment features Kevin Lundquist discussing his decision to join Outlook\nTherapeutics and the Company’s path forward following the FDA approval of\nLYTENAVA™\n\nAccess the segment here\n(https://www.globenewswire.com/Tracker?data=KPyvRMlou1T3hAaQt_65gBh1rw_Uwb2SlCKdyJZUlHSIFv_QCJmDMJoTDVsyn62aX6Zsl8m4deRJQWU3Axx7ms7SGpBQeDuvHhq9qgQEaMM=)\n\nISELIN, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=AipKltkhBnTWm5aJB47Gj1IR9w0rNoBEZVwehnE-aHvW5NsHzIHM3ufhCzKOP9o0S4FKDUZnIj-G2wuc-beRCA_PpeEA1ZUX0hoWTknULpyS8zbaZ5iQyTD4SX9clM5M)\n(Nasdaq: OTLK), a biopharmaceutical company focused on the development and\ncommercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the\ntreatment of retinal diseases, today announced that it participated in a\nVirtual Investor \"What This Means\" segment\n(https://www.globenewswire.com/Tracker?data=IpTaQlG9S2MeiDXnUMz4BkITBpe3gLZUs__jjAOmKbNWyPE2y75tTXckLd9ojX7nZLVdCG49Tnio6uGCga3hKMs7J2JBMciol19UpbKiW1yZolvfr4q7t7vW0vHgC5J1ikeKIcpt5soGEFhHuPEZdQ==)\nfeaturing Kevin Lundquist, the Company’s recently appointed Chief Financial\nOfficer\n\nIn the discussion, Mr. Lundquist shares his perspective on joining Outlook\nTherapeutics at such a pivotal time for the Company following the U.S. Food\nand Drug Administration approval of LYTENAVA, the only FDA-approved ophthalmic\nformulation of bevacizumab for the treatment of wet age-related macular\ndegeneration (wet AMD). He also discusses the opportunity ahead as Outlook\nTherapeutics advances toward the commercial launch of LYTENAVA in the United\nStates.\n\n“Joining Outlook Therapeutics at this point in the Company’s evolution was\na compelling opportunity,” said Kevin Lundquist, Chief Financial Officer of\nOutlook Therapeutics. “With FDA approval of LYTENAVA, we have entered an\nimportant new chapter as we transition into a commercial-stage company. I look\nforward to helping execute on our strategy, supporting the successful launch\nof LYTENAVA, and working to build long-term value for shareholders.”\n\nThe Virtual Investor “What This Means” segment is available to watch here\n(https://www.globenewswire.com/Tracker?data=KPyvRMlou1T3hAaQt_65gEi-AlR_EWh4DyJ0tQQIcnwVnt04K_zo_ooQTBEqjmnin_GBIXeJFprmUvch3vU35MNOJdCcXhgl_xSja3Tfnso=).\n\nAbout LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)\n\nLYTENAVA™ is an ophthalmic formulation of bevacizumab produced in the\nUnited States for the treatment of wet AMD. In the United States, LYTENAVA\n(bevacizumab-vikg) is the only ophthalmic formulation approved by the FDA.\nLYTENAVA (bevacizumab gamma) is also the subject of a centralized Marketing\nAuthorization granted by the European Commission in the EU and Marketing\nAuthorization granted by the Medicines and Healthcare products Regulatory\nAgency (MHRA) in the UK for the treatment of adults with wet AMD. In certain\nEuropean Union Member States, LYTENAVA must receive pricing and reimbursement\napproval before it can be sold.\n\nBevacizumab-vikg (bevacizumab gamma in the EU and UK) is a recombinant\nhumanized IgG1 monoclonal antibody specific to human vascular endothelial\ngrowth factor (VEGF). Bevacizumab binds VEGF and prevents the interaction of\nVEGF to its receptors (Flt-1 and KDR) on the surface of endothelial cells.\nLYTENAVA binds to all isoforms of VEGF-A, thereby preventing interaction with\nreceptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A, LYTENAVA suppresses\nendothelial cell proliferation, neovascularization, and vascular permeability.\nInhibition of such activity targets a pathophysiologic process that\ncontributes to vision loss.\n\nImportant Safety Information and Indication\n\nLYTENAVA (bevacizumab-vikg) is a vascular endothelial growth factor (VEGF)\ninhibitor indicated for the treatment of patients with neovascular (wet)\nage-related macular degeneration (nAMD).\n\nContraindications\n\nLYTENAVA is contraindicated in patients with ocular or periocular infections,\nin patients with active intraocular inflammation, and in patients with a known\nhypersensitivity to bevacizumab products or any of the ingredients in\nLYTENAVA. Hypersensitivity reactions may manifest as severe intraocular\ninflammation.\n\nWarnings and Precautions\n\nIntravitreal injections have been associated with endophthalmitis and retinal\ndetachments. Proper aseptic injection technique must always be used when\nadministering LYTENAVA. In addition, patients should be monitored following\nthe injection to permit early treatment should an infection occur.\n\nIncreases in intraocular pressure have been noted post-injection (up to 60\nminutes) while being treated with LYTENAVA. Monitor intraocular pressure prior\nto and following intravitreal injection with LYTENAVA and manage\nappropriately.\n\nAlthough there was a low rate of arterial thromboembolic events (ATEs)\nobserved in the LYTENAVA clinical trials, there is a potential risk of ATEs\nfollowing intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal\nstroke, nonfatal myocardial infarction, or vascular death (including deaths of\nunknown cause).\n\nAdverse Reactions\n\nThe most common adverse reactions (≥1%) reported in patients receiving\nLYTENAVA were conjunctival hemorrhage (4%), eye pain (2%), and vitreous\nfloaters (2%). These are not all the possible side effects of LYTENAVA.\n\nYou are encouraged to report side effects of prescription drugs to the FDA.\n\nVisit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side\neffects to Outlook Therapeutics at 1-833-999-OTLK (6855).\n\nPlease see the full U.S. Prescribing Information for LYTENAVA here.\n\nAbout Outlook Therapeutics, Inc.\n\nOutlook Therapeutics is a biopharmaceutical company focused on the development\nand commercialization of LYTENAVA (bevacizumab-vikg (U.S.), bevacizumab gamma\n(E.U.)). LYTENAVA is the only ophthalmic formulation of bevacizumab to receive\nU.S. FDA approval and European Commission and MHRA Marketing Authorization for\nthe treatment of wet AMD. Outlook Therapeutics commenced commercial launch of\nLYTENAVA (bevacizumab gamma) in Germany, Austria, and the UK as a treatment\nfor wet AMD.\n\nForward-Looking Statements\n\nThis press release contains statements that may or are considered\n“forward-looking statements”. All statements other than statements of\nhistorical facts are “forward-looking statements,” including those\nrelating to future events. In some cases, you can identify forward-looking\nstatements by terminology such as “anticipate,” “believe,” “can,”\n“could,” “continue,” “expect,” “may,” “on track,”\n“plan,” “potential,” “target,” “will,” or “would”, the\nnegative of terms like these or other comparable terminology, and other words\nor terms of similar meaning. These include, among others, express or implied\ndiscussions regarding the Company’s planned launch of LYTENAVA in the United\nStates and other jurisdictions and the timing thereof; expectations concerning\npotential revenue generation from sales of LYTENAVA; expectations surrounding\nmarket adoption of LYTENAVA; expectations regarding the potential impact of\nLYTENAVA in the retina community; Outlook Therapeutics’ development or\nfuture revenue plans for LYTENAVA generally; and other statements that are not\nhistorical fact. Although Outlook Therapeutics believes that it has a\nreasonable basis for the forward-looking statements contained herein, they are\nbased on current expectations about future events affecting Outlook\nTherapeutics and are subject to risks, uncertainties, and factors relating to\nits operations and business environment, all of which are difficult to predict\nand many of which are beyond its control. These risk factors include those\nrisks associated with developing and commercializing pharmaceutical product\ncandidates, risks in obtaining necessary regulatory approvals, the content and\ntiming of decisions by regulatory bodies, as well as those risks detailed in\nOutlook Therapeutics’ filings with the Securities and Exchange Commission\n(the SEC), including the Current Report on Form 8-K filed with the SEC on\nAugust 12, 2026 and the Quarterly Report on Form 10-Q for the quarter ended\nJune 30, 2026, and future reports Outlook Therapeutics files with the SEC,\nwhich include uncertainty of market conditions and future impacts related to\nmacroeconomic factors, including as a result of the ongoing overseas\nconflicts, tariffs, and trade tensions, fluctuations in interest rates and\ninflation, and potential future bank failures on the global business\nenvironment. These risks may cause actual results to differ materially from\nthose expressed or implied by forward-looking statements in this press\nrelease. All forward-looking statements included in this press release are\nexpressly qualified in their entirety by the foregoing cautionary statements.\nYou are cautioned not to place undue reliance on these forward-looking\nstatements, which speak only as of the date hereof. Outlook Therapeutics does\nnot undertake any obligation to update, amend, or clarify these\nforward-looking statements, whether as a result of new information, future\nevents, or otherwise, except as may be required under applicable securities\nlaw.\n\nInvestor Inquiries:\nJenene Thomas\nChief Executive Officer\nJTC Team, LLC\nT: 908.824.0775\nOTLK@jtcir.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/cbff3302-f8d2-466a-beff-8c33252f9c70)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-06T13:20:00.14216066Z","server_sent_at_ms":1791292800142},"received_at":"2026-10-06T13:20:00.193Z","source_url":null},"analysis":{"id":"150532","press_release_id":"162028","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"executive_change","narrative":"Outlook Therapeutics promoted a Virtual Investor segment featuring recently appointed CFO Kevin Lundquist discussing his decision to join the company.\n\nLundquist framed his arrival as part of the company's transition to a commercial-stage business following FDA approval of LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD.\n\nNo new financial results, guidance, or launch timing were disclosed in the release.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"PR interview rehash of previously announced CFO hire -- no incremental news."},"keyFigures":{},"quotedText":"With FDA approval of LYTENAVA, we have entered an important new chapter as we transition into a commercial-stage company.","namedEntities":{"people":[{"name":"Kevin Lundquist","role":"Chief Financial Officer"},{"name":"Jenene Thomas","role":"CEO, JTC Team (investor relations contact)"}],"products":["LYTENAVA (bevacizumab-vikg, bevacizumab gamma)"],"companies":[{"name":"Outlook Therapeutics, Inc.","ticker":"OTLK","relationship":"filer"},{"name":"Virtual Investor","relationship":"media segment host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Promotional PR rehashing an already-announced CFO appointment in a Virtual Investor segment; no new financial or operational information disclosed."},"tickerRelevance":{"others":[],"primary":"OTLK"},"globalImportance":10,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap biotech","eventGravity":"promotional interview, no new facts","issuerAuthored":true}},"event_type":"executive_change","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Outlook Therapeutics promoted a Virtual Investor segment featuring recently appointed CFO Kevin Lundquist discussing his decision to join the company.\n\nLundquist framed his arrival as part of the company's transition to a commercial-stage business following FDA approval of LYTENAVA, the only FDA-approved ophthalmic bevacizumab formulation for wet AMD.\n\nNo new financial results, guidance, or launch timing were disclosed in the release.","key_figures":{},"named_entities":{"people":[{"name":"Kevin Lundquist","role":"Chief Financial Officer"},{"name":"Jenene Thomas","role":"CEO, JTC Team (investor relations contact)"}],"products":["LYTENAVA (bevacizumab-vikg, bevacizumab gamma)"],"companies":[{"name":"Outlook Therapeutics, Inc.","ticker":"OTLK","relationship":"filer"},{"name":"Virtual Investor","relationship":"media segment host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-06T13:20:06.996Z","global_importance":10,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap biotech","eventGravity":"promotional interview, no new facts","issuerAuthored":true}},"durationMs":6768,"modelName":"glm-5.3-flashx"}}